Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 7/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.39 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL30838106 | 0.93 | CHRM3 (0.42) | CHRM3CCNA2CDK2PLK1CCNA1 | |
| Formic Acid SCHEMBL30838102 | 0.84 | VNN1 (0.55) | CYP11B1CYP11B2 | |
| Formic Acid SCHEMBL30838050 | 0.84 | VNN1 (0.55) | CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL30837986 | 0.83 | CHRM3 (0.47) | CHRM3HRH4NMT1 | |
| Formic Acid SCHEMBL30838073 | 0.83 | PRKCQ (0.41) | CYP11B1CYP11B2HRH4 | |
| Formic Acid SCHEMBL30838066 | 0.81 | HRH4 (0.44) | CYP11B1CYP11B2HRH4 | |
| SCHEMBL27095229 | 0.81 | VNN1 (0.42) | CYP11B1CYP11B2 | |
| Formic Acid SCHEMBL30838087 | 0.81 | HRH4 (0.41) | CYP11B1CYP11B2HRH4 | |
| Hydrochloric Acid SCHEMBL30838079 | 0.80 | NMT1 (0.51) | CHRM3HRH4NMT1 | |
| Fumaric Acid SCHEMBL30838065 | 0.80 | VNN1 (0.42) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CEREVANCE LTD (GB) | 2024-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CHRNA6, CHRM2, CHRNA1 | CHRM3 5/4885CCNA2 1910/4885CDK2 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.